Displayed in English — localised translation pending
blog
Last updated: 2025-09-19

2015.12.03 乳癌臨床實驗資訊

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
2015.12.03 乳癌臨床實驗資訊

2015.12.03 乳癌臨床實驗資訊

2015.12.03 乳癌臨床實驗資訊

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

乳癌臨床實驗資訊

  • 2015年12月3日
  • 讀畢需時 1 分鐘

針對乳癌患者,賀爾蒙受容體陽性、HER2且停經後的轉移性乳癌進行的第三階段臨床實驗,從2011.5~2017.12,在台灣、日本、美國等地皆有招募志願者,目標為525位。使用的藥品為Tykerp,中外製藥的 Herceptin兩種。相關的臨床實驗內容可以參考以下網頁。

http://www.clinicaltrials.jp/user/cteDetail.jsp?clinicalTrialId=6431

#乳癌

  • 臨床實驗用藥

   (肺癌)Topotecan及Topotecan+Berzosertib治療在第二期臨床試驗結果。   (肺癌)HER2基因變異非小細胞肺癌使用Enhertu有效?   (肺癌)抗B7-H3抗體藥物DS-7300有效?

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-409-5655
Formerly officially certified, No. B-066

圖片 1圖片 1

圖片 2圖片 2

圖片 3圖片 3

圖片 4圖片 4

相關癌症資訊

Related Reading